The rationale behind developing therapeutic strategies in breast cancer, targeting signaling components of the IGF pathway, derives from the evidence supporting the direct and intricate implication of the IGF-1 and IGF-2 ligands and their receptors, mainly IGF-1R, in breast cancer initiation and progression. This evidence concerns the gene IGF1R and breast cancer.